title: Uncoupling PSD-95 interactions leads to rapid recovery of cortical function after focal stroke.
abstract: Since the most significant ischemic sequelae occur within hours of stroke, it is necessary to understand how neuronal function changes during this time. While histologic and behavioral models show the extent of stroke-related damage, only in vivo recordings can illustrate changes in brain activity during stroke and validate effectiveness of neuroprotective compounds. Spontaneous and evoked field potentials (fEPs) were recorded in the deep layers of the cortex with a linear microelectrode array for 3 hours after focal stroke in anesthetized rats. Tat-NR2B9c peptide, which confers neuroprotection by uncoupling the PSD-95 protein from N-methyl-D-aspartate receptor (NMDAR), was administered 5 minutes before ischemia. Evoked field potentials were completely suppressed within 3 minutes of infarct in all ischemic groups. Evoked field potential recovery after stroke in rats treated with Tat-NR2B9c (83% of baseline) was greater compared with stroke-only (61% of baseline) or control peptide (Tat-NR2B-AA; 67% of baseline) groups (P<0.001). Electroencephalography (EEG) power was higher in Tat-NR2B9c-treated animals at both 20 minutes and 1 hour (50% and 73% of baseline, respectively) compared with stroke-only and Tat-NR2B-AA-treated rats (P<0.05). Tat-NR2B9c significantly reduces stroke-related cortical dysfunction as evidenced by greater recovery of fEPs and EEG power; illustrating the immediate effects of the compound on poststroke brain function.
authors.affiliation: Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Luka R
authors.initials: LR
authors.lastname: Srejic
authors.forename: William D
authors.initials: WD
authors.lastname: Hutchison
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Aarts
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000503:physiopathology*; D000076122:Disks Large Homolog 4 Protein; D005071:Evoked Potentials / Q000187:drug effects; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism
chemical_list: D000076122:Disks Large Homolog 4 Protein; C501449:Dlg4 protein, rat; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D018696:Neuroprotective Agents; D010455:Peptides; D016194:Receptors, N-Methyl-D-Aspartate; C542597:Tat-NR2B9c
references.citation: Neurology. 1998 Sep;51(3 Suppl 3):S44-6
references.pmid: 9744833
references.citation: Science. 2013 Jun 28;340(6140):1591-4
references.pmid: 23812718
references.citation: Eur J Neurosci. 2006 Dec;24(12):3553-60
references.pmid: 17229103
references.citation: Psychopharmacol Bull. 1994;30(4):533-40
references.pmid: 7770617
references.citation: Neuron. 2008 Jan 24;57(2):248-62
references.pmid: 18215622
references.citation: Stroke. 1995 Feb;26(2):254-8
references.pmid: 7831698
references.citation: Neuropharmacology. 2007 Jan;52(1):71-6
references.pmid: 16899258
references.citation: Adv Neurol. 1996;71:75-83; discussion 83-4
references.pmid: 8790792
references.citation: Science. 2002 Oct 25;298(5594):846-50
references.pmid: 12399596
references.citation: J Neurosci. 2012 Sep 26;32(39):13510-9
references.pmid: 23015440
references.citation: Science. 1995 Sep 22;269(5231):1737-40
references.pmid: 7569905
references.citation: Neuropharmacology. 2007 Jan;52(1):60-70
references.pmid: 16904707
references.citation: Stroke. 1981 Nov-Dec;12(6):723-5
references.pmid: 6272455
references.citation: Trends Neurosci. 1999 Sep;22(9):391-7
references.pmid: 10441299
references.citation: Anat Rec. 1982 Jul;203(3):397-404
references.pmid: 7137595
references.citation: Stroke. 2008 Sep;39(9):2544-53
references.pmid: 18617669
references.citation: Stroke. 1977 Jan-Feb;8(1):51-7
references.pmid: 13521
references.citation: Mol Brain. 2010 Sep 16;3:27
references.pmid: 20846411
references.citation: Neuroscientist. 2003 Feb;9(1):64-75
references.pmid: 12580341
references.citation: Br J Pharmacol. 1983 Jun;79(2):461-9
references.pmid: 6652337
references.citation: Nature. 2010 Nov 11;468(7321):305-9
references.pmid: 21048709
references.citation: Nat Neurosci. 2011 Oct 26;14(11):1369-73
references.pmid: 22030547
references.citation: J Physiol. 2003 Feb 1;546(Pt 3):859-67
references.pmid: 12563010
references.citation: J Neurochem. 2013 Jul;126(2):274-87
references.pmid: 23363435
references.citation: Nat Rev Neurosci. 2009 Dec;10(12):861-72
references.pmid: 19888284
references.citation: Brain. 2003 Feb;126(Pt 2):470-81
references.pmid: 12538413
references.citation: Stroke. 1990 Jan;21(1):124-32
references.pmid: 2300979
references.citation: Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1989-96
references.pmid: 15498820
references.citation: J Neurophysiol. 1990 Nov;64(5):1527-36
references.pmid: 2283539
references.citation: J Neurosurg. 2013 May;118(5):1098-106
references.pmid: 23413946
references.citation: Science. 1999 Jun 11;284(5421):1845-8
references.pmid: 10364559
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4176-81
references.pmid: 17360496
references.citation: Neuropharmacology. 1986 Jun;25(6):639-43
references.pmid: 3748317
references.citation: Lancet Neurol. 2012 Nov;11(11):942-50
references.pmid: 23051991
references.citation: Neuropharmacology. 2008 Sep;55(3):363-89
references.pmid: 18308347
references.citation: Nature. 1998 Dec 3;396(6710):433-9
references.pmid: 9853749
references.citation: Brain. 2012 Jun;135(Pt 6):1884-99
references.pmid: 22561640
references.citation: J Cereb Blood Flow Metab. 2012 Jun;32(6):1035-45
references.pmid: 22373645
references.citation: Nature. 2012 Feb 29;483(7388):213-7
references.pmid: 22388811